ImmuneDiscover Phase 1
| Reference number | |
| Coordinator | ImmuneDiscover Sweden AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | June 2020 - December 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2020 |
Important results from the project
The goal of the project is to develop ImmuneDiscover Sweden AB, a company that offers unique technologies for identifying genetic variation in human immune receptor genes. Traditional gene sequencing methods do not provide sufficient accuracy for these complex gene regions. Since 2015, we have developed technologies and software that solve this problem and can be used to explain why people respond differently to vaccination and infections, and why some people develop autoimmune diseases, cancer, or allergies.
Expected long term effects
Our Phase 1 grant from Vinnova has made it possible to carry out several activities, which means that the company is now in a completely different development phase than before we received the grant. We have established routines for financial accounting and legal consultation, and we have developed materials for discussions with potential customers. We have also established a website, conducted market research, and identified advisors. These results are consistent with the expected outcomes.
Approach and implementation
The organization and implementation of the work has progressed according to plan. The work was performed by Gunilla Karlsson Hedestam and Martin Corcoran.